Press release
Rottapharm's Documentation goes paperless with PAS-X
Rottapharm's production site in Dublin (Source: Rottapharm)
Lueneburg, Germany, September 8, 2009 - The Italian pharma group Rottapharm is introducing PAS-X at its Irish production site in Dublin. With the transition towards paperless production and documentation, the multinational company will be making its production processes more efficient and increasing output levels. Werum will be implementing a complete PAS-X-based MES, including integration with the SCADA level.
Rottapharm manufactures ethical pharmaceuticals, over the counter and non-prescription drugs, personal care products and nutritional supplements. The therapeutic focus of the pharmaceutical products is cardiology, gastroenterology, gynecology, urology and rheumatology.
Rottapharm established operations in Ireland in 1999. In Dublin, Rottapharm is investing seven million Euros in three new manufacturing and associated packaging lines, which will create 35 jobs and add 2000 square meters. The site employs 150 people in total and primarily manufactures capsule, sachet and tablet forms of the Glucosamine Sulfate Dona, a drug for treating osteoarthritis. The facility also produces the API for Dona.
Werum Software & Systems (www.werum.com) is the leading supplier of Manufacturing Execution Systems (MES) for the pharmaceutical and bio-pharmaceutical industries worldwide. Fourteen of the world's top 20 pharmaceutical companies and leading biotech companies use Werum's MES product suite PAS-X to run their manufacturing business. Outstanding PAS-X features are the functions ensuring compliance and boosting performance. Werum's solutions and services range from software consulting, creation of functional specifications, and software development to turn-key delivery of integrated and validated MES. A global partner network ensures reliable local support services. Founded in 1969, the IT company employs 315 people at different locations. Werum is headquartered in Lueneburg (Northern Germany) and has regional offices in St. Augustin and Hausach. Its U.S. subsidiary Werum America is headquartered in Parsippany, New Jersey, and has additional offices in Cary, North Carolina, and in Pasadena, California.
Werum Software & Systems, Tel. USA +1 (973) 644-4000, Tel. Europe +49 (0)4131 8900-0, Press Contact: Volker Mensing, mensing@werum.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Rottapharm's Documentation goes paperless with PAS-X here
News-ID: 95879 • Views: …
More Releases from Werum Software & Systems
13th PAS-X User Group Meeting in Germany
13th PAS-X User Group Meeting in Germany
Werum Manufacturing IT Conference with record attendance
Lueneburg, Germany, 26 October 2011 – The 13th international PAS-X User Group Meeting took place from 13 to 14 October 2011 in Lueneburg, Germany, with a record attendance. On the invitation of Werum Software & Systems AG, almost 200 pharmaceuticals experts from approximately 20 countries exchanged their thoughts and ideas on the use of the PAS-X production management…
Indian pharmaceutical major Dr. Reddy's chooses to implement Werum's MES
Dr. Reddy's Laboratories Ltd. deploys PAS-X at Hyderabad site
Lueneburg, Germany, August 20, 2010 – Dr. Reddy's Laboratories Ltd. has decided to introduce PAS-X, the Manufacturing Execution System (MES) by Werum Software & Systems, at its site in Bachupally, Hyderabad.
Dr. Reddy's plans to optimize the efficiency, quality, compliance and performance of its production processes with PAS-X. Werum is the leading supplier of MES systems for the pharmaceutical and biopharmaceutical industries…
MSD Packaging Lines run with PAS-X
Lueneburg, Germany, August 17, 2010 - MSD deployed PAS-X, the Manufacturing Execution System (MES) by Werum Software & Systems, to run its packaging line operations in Heist-op-den-Berg, Belgium in order to increase the compliance level during packaging operations and subsequently shorten lead times to improve delivery performance. Operations include fully automated blister lines and filling lines, semi-automated packaging lines and manual packaging processes. The project for introducing PAS-X was completed…
Successful rollout of PAS-X MES Weighing & Dispensing at AstraZeneca in India an …
Manufacturing Execution System projects completed successfully
Lueneburg, Germany, March 25, 2010 - Manufacturing Execution System (MES) software provider Werum Software & Systems has successfully finalized the installation of PAS-X MES in AstraZeneca's Wuxi site in the Jiangsu Province, China. This first-time MES project in the Chinese pharmaceutical industry follows an employment of Werum's PAS-X MES software in AstraZeneca's Indian production site in Bengaluru (formerly Bangalore) in 2009.
Both MES projects are part…
More Releases for Rottapharm
Hyperuricemia Therapeutic Market Personalized Medicine Is Shaping the Future Sec …
The Global Hyperuricemia Therapeutic Market is estimated to be valued at USD 2.2 billion in 2024 and is expected to reach USD 3.1 billion by 2031, growing at a compound annual growth rate (CAGR) of 5.2% from 2024 to 2031.Latest Report, titled ""Hyperuricemia Therapeutic Market"" Trends, Share, Size, Growth, Opportunity and Forecast 2024-2031, by C
CoherentMI offers a comprehensive analysis of the industry, which comprises insights on the market analysis. The…
Herbal Medicines Market Is in Huge Demand: Tsumura, Rottapharm Madaus GmbH, Wele …
Advance Market Analytics added research publication document on Worldwide Herbal Medicines Market breaking major business segments and highlighting wider level geographies to get deep dive analysis on market data. The study is a perfect balance bridging both qualitative and quantitative information of Worldwide Herbal Medicines market. The study provides valuable market size data for historical (Volume** & Value) from 2018 to 2023 which is estimated and forecasted till 2028*. Some…
Irritable Bowel Syndrome (IBS) Market Poised for Phenomenal Expansion During the …
The Irritable Bowel Syndrome Market size in the 7MM was approximately USD 1,800 million in 2022, and it is projected to increase during the forecast period. As per DelveInsight, the Irritable Bowel Syndrome Market is anticipated to evolve immensely in the coming years owing to the rise in the geriatric population, the increase in the prevalence of gastrointestinal diseases and disorders, unhealthy diets, and the expected commercial success of upcoming…
Obsessive-Compulsive Disorder Treatment Market To Grow Extensively At Unstoppabl …
A recent market research report added to repository of MR Accuracy Reports is an in-depth analysis of global Obsessive-Compulsive Disorder Treatment. On the basis of historic growth analysis and current scenario of Obsessive-Compulsive Disorder Treatment place, the report intends to offer actionable insights on global market growth projections. Authenticated data presented in report is based on findings of extensive primary and secondary research. Insights drawn from data serve as excellent…
Cholecystokinin Receptor (CCK) Antagonist Market 2020 New Innovations in Medical …
Cholecystokinin Receptor (CCK) Antagonist -Pipeline Insight, 2020
The report will make detailed analysis mainly on in-depth research on the development environment, Market size, development trend, operation situation and future development trend of Cholecystokinin Receptor (CCK) Antagonist Market on the basis of stating current situation of the industry in 2020.
This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of…
Diacerein Market potential growth, share, demand and analysis of key players - r …
This detailed market study covers diacerein market growth potentials which can assist the stake holders to understand key trends and prospects in diacerein market identifying the growth opportunities and competitive scenarios. The report also focuses on data from different primary and secondary sources, and is analyzed using various tools. It helps to gain insights into the market's growth potential, which can help investors identify scope and opportunities. The analysis also…
